Gil Morgan MD
@weoncologists.bsky.social
Clinical Oncologist from Texas🇺🇸 @oncoalert.bsky.social Representative 🚨 Proudly NIH, NCI & MDA trained. An ounce of prevention equals a pound of cure. Views are own🌏
Reposted by Gil Morgan MD
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Jonathan Zager 🇺🇸 Moffit Cancer Center Presenting on Melanoma Staging and Molecular Testing
Presentation reviews current AJCC staging system for melanoma, outline present state of staging practices, and explore potential areas for refinement
Presentation reviews current AJCC staging system for melanoma, outline present state of staging practices, and explore potential areas for refinement
October 15, 2025 at 12:02 PM
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Jonathan Zager 🇺🇸 Moffit Cancer Center Presenting on Melanoma Staging and Molecular Testing
Presentation reviews current AJCC staging system for melanoma, outline present state of staging practices, and explore potential areas for refinement
Presentation reviews current AJCC staging system for melanoma, outline present state of staging practices, and explore potential areas for refinement
Reposted by Gil Morgan MD
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Øyvind Bruland 🇳🇴 Oslo
Alpha-emitting Radionuclide-Therapy with Bio-degradable microparticles injected intra-peritoneally
Alpha-emitting Radionuclide-Therapy with Bio-degradable microparticles injected intra-peritoneally
October 15, 2025 at 1:45 PM
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Øyvind Bruland 🇳🇴 Oslo
Alpha-emitting Radionuclide-Therapy with Bio-degradable microparticles injected intra-peritoneally
Alpha-emitting Radionuclide-Therapy with Bio-degradable microparticles injected intra-peritoneally
Reposted by Gil Morgan MD
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Markus Mille 🇩🇪
Discussing: Robotic Single Port SP Surgery
Robotic single-port (SP) surgery, enabled by the da Vinci SP system, represents an advanced evolution in robotic-assisted surgery
Discussing: Robotic Single Port SP Surgery
Robotic single-port (SP) surgery, enabled by the da Vinci SP system, represents an advanced evolution in robotic-assisted surgery
October 15, 2025 at 3:10 PM
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Markus Mille 🇩🇪
Discussing: Robotic Single Port SP Surgery
Robotic single-port (SP) surgery, enabled by the da Vinci SP system, represents an advanced evolution in robotic-assisted surgery
Discussing: Robotic Single Port SP Surgery
Robotic single-port (SP) surgery, enabled by the da Vinci SP system, represents an advanced evolution in robotic-assisted surgery
Reposted by Gil Morgan MD
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Anders Thornell 🇸🇪 Sahlgrenska
Mock Debate: Should follow-up for operated GIST tumors be escalated or de-escalated?
Two experts go head-to-head over early relapse detection, second cancer risk, scan burden, and guideline evolution.
Mock Debate: Should follow-up for operated GIST tumors be escalated or de-escalated?
Two experts go head-to-head over early relapse detection, second cancer risk, scan burden, and guideline evolution.
October 15, 2025 at 9:02 AM
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Anders Thornell 🇸🇪 Sahlgrenska
Mock Debate: Should follow-up for operated GIST tumors be escalated or de-escalated?
Two experts go head-to-head over early relapse detection, second cancer risk, scan burden, and guideline evolution.
Mock Debate: Should follow-up for operated GIST tumors be escalated or de-escalated?
Two experts go head-to-head over early relapse detection, second cancer risk, scan burden, and guideline evolution.
Reposted by Gil Morgan MD
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Laura Lorenzon 🇮🇹
Investigation and Management of GI Symptoms After Surgery
This presentation highlights the main dimensions related to quality of life, the main metrics used to measure symptoms and the main issues in this field
Investigation and Management of GI Symptoms After Surgery
This presentation highlights the main dimensions related to quality of life, the main metrics used to measure symptoms and the main issues in this field
October 15, 2025 at 12:20 PM
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Laura Lorenzon 🇮🇹
Investigation and Management of GI Symptoms After Surgery
This presentation highlights the main dimensions related to quality of life, the main metrics used to measure symptoms and the main issues in this field
Investigation and Management of GI Symptoms After Surgery
This presentation highlights the main dimensions related to quality of life, the main metrics used to measure symptoms and the main issues in this field
Reposted by Gil Morgan MD
Day 2 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Stefan Stättner 🇦🇹
Discussing Robotic Liver Surgery
Robotic liver surgery is moving from the acceptance to the standardization phase with emerging experience and higher availability of robotic systems.
Discussing Robotic Liver Surgery
Robotic liver surgery is moving from the acceptance to the standardization phase with emerging experience and higher availability of robotic systems.
October 15, 2025 at 2:55 PM
Day 2 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Stefan Stättner 🇦🇹
Discussing Robotic Liver Surgery
Robotic liver surgery is moving from the acceptance to the standardization phase with emerging experience and higher availability of robotic systems.
Discussing Robotic Liver Surgery
Robotic liver surgery is moving from the acceptance to the standardization phase with emerging experience and higher availability of robotic systems.
Reposted by Gil Morgan MD
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Wim Ceelen 🇧🇪 Ghent
Physically Enhanced IP Drug Delivery
Tumor tissue penetration is very limited after intraperitoneal drug delivery, hampering its clinical efficacy. I discuss how physical methods overcome transport barriers.
Physically Enhanced IP Drug Delivery
Tumor tissue penetration is very limited after intraperitoneal drug delivery, hampering its clinical efficacy. I discuss how physical methods overcome transport barriers.
October 15, 2025 at 2:03 PM
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Wim Ceelen 🇧🇪 Ghent
Physically Enhanced IP Drug Delivery
Tumor tissue penetration is very limited after intraperitoneal drug delivery, hampering its clinical efficacy. I discuss how physical methods overcome transport barriers.
Physically Enhanced IP Drug Delivery
Tumor tissue penetration is very limited after intraperitoneal drug delivery, hampering its clinical efficacy. I discuss how physical methods overcome transport barriers.
Reposted by Gil Morgan MD
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Elinor Bexe Lindskog 🇸🇪
The Immune Microenvironment in Peritoneal Metastases
The immune landscape of peritoneal metastases differs from other metastatic sites. Peritoneal lesions show a fibro-inflammatory, immune-regulated niche
The Immune Microenvironment in Peritoneal Metastases
The immune landscape of peritoneal metastases differs from other metastatic sites. Peritoneal lesions show a fibro-inflammatory, immune-regulated niche
October 15, 2025 at 7:00 AM
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Elinor Bexe Lindskog 🇸🇪
The Immune Microenvironment in Peritoneal Metastases
The immune landscape of peritoneal metastases differs from other metastatic sites. Peritoneal lesions show a fibro-inflammatory, immune-regulated niche
The Immune Microenvironment in Peritoneal Metastases
The immune landscape of peritoneal metastases differs from other metastatic sites. Peritoneal lesions show a fibro-inflammatory, immune-regulated niche
Reposted by Gil Morgan MD
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Lasma Nikolaisone 🇱🇻
The Testimonial of a Young Rectal Cancer Patient
Rectal cancer treatment saves lives — but what follows is often a silent struggle with side effects that few discuss openly #RectalCancer
The Testimonial of a Young Rectal Cancer Patient
Rectal cancer treatment saves lives — but what follows is often a silent struggle with side effects that few discuss openly #RectalCancer
October 15, 2025 at 1:15 PM
Day 1 of #ESSO44 in Gothenburg Sweden, Presentation by Dr. Lasma Nikolaisone 🇱🇻
The Testimonial of a Young Rectal Cancer Patient
Rectal cancer treatment saves lives — but what follows is often a silent struggle with side effects that few discuss openly #RectalCancer
The Testimonial of a Young Rectal Cancer Patient
Rectal cancer treatment saves lives — but what follows is often a silent struggle with side effects that few discuss openly #RectalCancer
Reposted by Gil Morgan MD
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
September 30, 2025 at 11:42 AM
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
Reposted by Gil Morgan MD
See you in Berlin for #ESMO25!
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.
October 3, 2025 at 9:32 AM
See you in Berlin for #ESMO25!
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.
The OncoAlert AF is ready to bring you all the great science coming out of Germany🇩🇪 .
We encourage you to follow these outstanding colleagues, and—as always—OncoAlert will be on the ground reporting in real time on all the latest news and trials.
Reposted by Gil Morgan MD
A warm welcome to the 43rd Annual CFS, NOW VIRTUAL (LIVE OR ONLINE) !!
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) tinyurl.com/3ak6zm6s
A great 3 day conference for health care professionals focused on evidence-based, state-of-the-art cancer care. SIGN UP FOR FREE VIRTUAL REGISTRATION!
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) tinyurl.com/3ak6zm6s
A great 3 day conference for health care professionals focused on evidence-based, state-of-the-art cancer care. SIGN UP FOR FREE VIRTUAL REGISTRATION!
October 3, 2025 at 1:36 PM
A warm welcome to the 43rd Annual CFS, NOW VIRTUAL (LIVE OR ONLINE) !!
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) tinyurl.com/3ak6zm6s
A great 3 day conference for health care professionals focused on evidence-based, state-of-the-art cancer care. SIGN UP FOR FREE VIRTUAL REGISTRATION!
HCP's Register FOR FREE 👉 (USE CODE: ONCOALERT ) tinyurl.com/3ak6zm6s
A great 3 day conference for health care professionals focused on evidence-based, state-of-the-art cancer care. SIGN UP FOR FREE VIRTUAL REGISTRATION!
Reposted by Gil Morgan MD
NEWS FROM INDUSTRY: UPDATE ON TROPION-Breast02 #BreastCancer
Source European Pharmaceutical Review, Astrazeneca, Daiichi Sankyo
www.europeanpharmaceuticalreview.com/news/266702/...
The phase III TROPION-Breast02 trial showed that the ADC Datopotamab Deruxtecandlnk significantly improved OS & PFS
Source European Pharmaceutical Review, Astrazeneca, Daiichi Sankyo
www.europeanpharmaceuticalreview.com/news/266702/...
The phase III TROPION-Breast02 trial showed that the ADC Datopotamab Deruxtecandlnk significantly improved OS & PFS
October 6, 2025 at 10:44 AM
NEWS FROM INDUSTRY: UPDATE ON TROPION-Breast02 #BreastCancer
Source European Pharmaceutical Review, Astrazeneca, Daiichi Sankyo
www.europeanpharmaceuticalreview.com/news/266702/...
The phase III TROPION-Breast02 trial showed that the ADC Datopotamab Deruxtecandlnk significantly improved OS & PFS
Source European Pharmaceutical Review, Astrazeneca, Daiichi Sankyo
www.europeanpharmaceuticalreview.com/news/266702/...
The phase III TROPION-Breast02 trial showed that the ADC Datopotamab Deruxtecandlnk significantly improved OS & PFS
Reposted by Gil Morgan MD
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
October 7, 2025 at 9:30 AM
Efficacy and safety of systemic therapies following progression on CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: a systematic review and network meta-analysis
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Reposted by Gil Morgan MD
The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
October 8, 2025 at 10:15 AM
The OncoAlert #GUCancer Faculty, led by Dr. Natalia Gandur🇦🇷 , Dr. Regina Barragan🇲🇽 & Dr. Gil Morgan🇺🇸 have selected the OncoAlert TOP🔟 #ESMO25 Abstracts In #ProstateCancer, #KidneyCancer #BladderCancer and #PenisCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.
Reposted by Gil Morgan MD
Oncology Here & NOW S2E3 in #BreastCancer
with @elisaagostinetto.bsky.social & @erikahamilton9.bsky.social discussing:
✅Current & emerging treatments
✅Patient selection
✅T-DXd + pertuzumab
✅ILD management & more
@hoperugo.bsky.social @elisabettabonzano.bsky.social
youtu.be/YdUX52c22Ig
with @elisaagostinetto.bsky.social & @erikahamilton9.bsky.social discussing:
✅Current & emerging treatments
✅Patient selection
✅T-DXd + pertuzumab
✅ILD management & more
@hoperugo.bsky.social @elisabettabonzano.bsky.social
youtu.be/YdUX52c22Ig
Oncology Here and Now podcast (Breast Cancer) S02E03 w/ Dr. Erika Hamilton and Dr. Elisa Agostinetto
YouTube video by OncoAlert 360
youtu.be
October 6, 2025 at 2:06 PM
Oncology Here & NOW S2E3 in #BreastCancer
with @elisaagostinetto.bsky.social & @erikahamilton9.bsky.social discussing:
✅Current & emerging treatments
✅Patient selection
✅T-DXd + pertuzumab
✅ILD management & more
@hoperugo.bsky.social @elisabettabonzano.bsky.social
youtu.be/YdUX52c22Ig
with @elisaagostinetto.bsky.social & @erikahamilton9.bsky.social discussing:
✅Current & emerging treatments
✅Patient selection
✅T-DXd + pertuzumab
✅ILD management & more
@hoperugo.bsky.social @elisabettabonzano.bsky.social
youtu.be/YdUX52c22Ig
Reposted by Gil Morgan MD
A Great Day One of #IUCS25 Great Presentation by Dr. Partha Choudhury
The Theranostic Revolution
✨ Early randomized results look promising
🎯 Time to reimagine dosimetry & radionuclide choice for optimized delivery
#ProstateCancer
The Theranostic Revolution
✨ Early randomized results look promising
🎯 Time to reimagine dosimetry & radionuclide choice for optimized delivery
#ProstateCancer
September 4, 2025 at 2:02 PM
A Great Day One of #IUCS25 Great Presentation by Dr. Partha Choudhury
The Theranostic Revolution
✨ Early randomized results look promising
🎯 Time to reimagine dosimetry & radionuclide choice for optimized delivery
#ProstateCancer
The Theranostic Revolution
✨ Early randomized results look promising
🎯 Time to reimagine dosimetry & radionuclide choice for optimized delivery
#ProstateCancer
Reposted by Gil Morgan MD
A Great Day One of #IUCS25 Great Presentation by Dr. Sara Rebuzzi 🇮🇹
⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways
✅ Feasible in selected patients, with potential for long-term disease control
✅ Reduced toxicity burden vs continuous therapy
📊 Stronger evidence with ICI than TKI
⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways
✅ Feasible in selected patients, with potential for long-term disease control
✅ Reduced toxicity burden vs continuous therapy
📊 Stronger evidence with ICI than TKI
September 4, 2025 at 3:25 PM
A Great Day One of #IUCS25 Great Presentation by Dr. Sara Rebuzzi 🇮🇹
⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways
✅ Feasible in selected patients, with potential for long-term disease control
✅ Reduced toxicity burden vs continuous therapy
📊 Stronger evidence with ICI than TKI
⏸️ Treatment Breaks in #KidneyCancer – Key Takeaways
✅ Feasible in selected patients, with potential for long-term disease control
✅ Reduced toxicity burden vs continuous therapy
📊 Stronger evidence with ICI than TKI
Reposted by Gil Morgan MD
Day2⃣of #IUCS25 🇬🇧Portsmouth
Dr. Enrique Grande 🇪🇸 discusses “Geting more patient the right 1st line in Bladder Cancer.”
👉 improving patient selection, refining dosing strategies, and developing predictive tools are key to making sure more patients receive and benefit the right first-line tx
Dr. Enrique Grande 🇪🇸 discusses “Geting more patient the right 1st line in Bladder Cancer.”
👉 improving patient selection, refining dosing strategies, and developing predictive tools are key to making sure more patients receive and benefit the right first-line tx
September 5, 2025 at 8:29 AM
Day2⃣of #IUCS25 🇬🇧Portsmouth
Dr. Enrique Grande 🇪🇸 discusses “Geting more patient the right 1st line in Bladder Cancer.”
👉 improving patient selection, refining dosing strategies, and developing predictive tools are key to making sure more patients receive and benefit the right first-line tx
Dr. Enrique Grande 🇪🇸 discusses “Geting more patient the right 1st line in Bladder Cancer.”
👉 improving patient selection, refining dosing strategies, and developing predictive tools are key to making sure more patients receive and benefit the right first-line tx
Reposted by Gil Morgan MD
Day2⃣of #IUCS25 🇬🇧Portsmouth
Dr. Petros Grivas🇺🇸 discusses “How Perioperative Treatment is Evolving in Bladder Cancer.”
📌 The perioperative space in MIBC is rapidly transforming—biomarkers, immunotherapy, ADCs, and combinations are reshaping the standard of care.
Dr. Petros Grivas🇺🇸 discusses “How Perioperative Treatment is Evolving in Bladder Cancer.”
📌 The perioperative space in MIBC is rapidly transforming—biomarkers, immunotherapy, ADCs, and combinations are reshaping the standard of care.
September 5, 2025 at 8:50 AM
Day2⃣of #IUCS25 🇬🇧Portsmouth
Dr. Petros Grivas🇺🇸 discusses “How Perioperative Treatment is Evolving in Bladder Cancer.”
📌 The perioperative space in MIBC is rapidly transforming—biomarkers, immunotherapy, ADCs, and combinations are reshaping the standard of care.
Dr. Petros Grivas🇺🇸 discusses “How Perioperative Treatment is Evolving in Bladder Cancer.”
📌 The perioperative space in MIBC is rapidly transforming—biomarkers, immunotherapy, ADCs, and combinations are reshaping the standard of care.
Reposted by Gil Morgan MD
The OncoAlert WEEKLY RoundUp 🚨
Covering the TOP of the week Aug 28-Sept 4, 2025
REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/maThWN36_sc
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social
Covering the TOP of the week Aug 28-Sept 4, 2025
REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/maThWN36_sc
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social
OncoAlert Weekly Round Up🚨 Aug 29-Sept 4 Covering ASTER70, CodeBreak300 IMmotion010 and more
YouTube video by OncoAlert 360
youtu.be
September 5, 2025 at 12:05 PM
The OncoAlert WEEKLY RoundUp 🚨
Covering the TOP of the week Aug 28-Sept 4, 2025
REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/maThWN36_sc
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social
Covering the TOP of the week Aug 28-Sept 4, 2025
REGISTER HERE👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/maThWN36_sc
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @fumikochino.bsky.social @agerikssonmd.bsky.social
Reposted by Gil Morgan MD
Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! 👉 FREE HCP Registration (USE CODE: ONCOALERT )🚨
buff.ly/KVngjav
Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates in GI
buff.ly/KVngjav
Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates in GI
August 21, 2025 at 12:02 PM
Experience the 2025 International Symposium of Gastrointestinal Oncology (ISGIO) LIVE in Austin Tx or Streamed ONLINE ! 👉 FREE HCP Registration (USE CODE: ONCOALERT )🚨
buff.ly/KVngjav
Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates in GI
buff.ly/KVngjav
Join leading experts for two days of case-based learning, interactive panels, and cutting-edge updates in GI
Reposted by Gil Morgan MD
You're invited to watch the Post-ASCO 2025 Lung Cancer Highlights webinar by @VJOncology 🫁 Watch Here 👉 bit.ly/4o14fdK
Featuring expert presentations and in-depth discussions on key abstracts in #Lungcancer presented at ASCO 2025.
Featuring expert presentations and in-depth discussions on key abstracts in #Lungcancer presented at ASCO 2025.
August 21, 2025 at 12:45 PM
You're invited to watch the Post-ASCO 2025 Lung Cancer Highlights webinar by @VJOncology 🫁 Watch Here 👉 bit.ly/4o14fdK
Featuring expert presentations and in-depth discussions on key abstracts in #Lungcancer presented at ASCO 2025.
Featuring expert presentations and in-depth discussions on key abstracts in #Lungcancer presented at ASCO 2025.
Reposted by Gil Morgan MD
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 15-21, 2025
youtu.be/4DAcGeK-Qac
REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/4DAcGeK-Qac
REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
OncoAlert Weekly Roundup🚨 August 15-21, 2025 / AMPLIFY201, IMvigor011 Update in #BladderCancer
🎯 Personalization in Cancer Care | OncoAlert Weekly Roundup (Breast, Bladder, GI, Lung, Prostate & More)
Description:
Welcome to this week’s OncoAlert Weekly Roundup—your 4-minute source for the…
youtu.be
August 21, 2025 at 4:09 PM
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week August 15-21, 2025
youtu.be/4DAcGeK-Qac
REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/4DAcGeK-Qac
REGISTER at ww.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
Reposted by Gil Morgan MD
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
www.sciencedirect.com/science/arti...
This international four-phase study (2022–2024) sought to modernize health-related quality of life (HRQOL) assessment tools
www.sciencedirect.com/science/arti...
This international four-phase study (2022–2024) sought to modernize health-related quality of life (HRQOL) assessment tools
August 22, 2025 at 11:37 AM
Development of a Health-related Quality of Life Questionnaire for Patients with Metastatic or Localized Renal Cell Carcinoma
www.sciencedirect.com/science/arti...
This international four-phase study (2022–2024) sought to modernize health-related quality of life (HRQOL) assessment tools
www.sciencedirect.com/science/arti...
This international four-phase study (2022–2024) sought to modernize health-related quality of life (HRQOL) assessment tools